Fatty liver, hypertension, and the metabolic syndrome

Gut

Volumn 53, Issue 7, 2004, Pages 923-924

  Diehl, A M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; METFORMIN;

BLOOD ANALYSIS; BODY WEIGHT; DIABETES MELLITUS; DYSLIPIDEMIA; ECHOGRAPHY; FATTY LIVER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIVER METABOLISM; METABOLIC SYNDROME X; NONHUMAN; NOTE; OBESITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL;

FATTY LIVER; HUMANS; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X;

EID: 3042628302     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.037309     Document Type: Note

References (30)

1. Bellentoni S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-17.
2. Younossi Z, Diehl AM, Ong J. Nonalcoholic fatty lier disease: an agenda for clinical research. Hepatology 2002;35:746-52.
3. Powell EE, Cooksley GE, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow-up study of 42 patients follow for up to 21 years. Hepatology 1990;11:74-80.
4. Teli M, James OF, Burt AD, et al. A natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995;22:1714-19.
5. Falck-Ytter Y, Younassi ZM, Marchesini G, et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin liver Dis 2001;21:71-6.
6. Van Waes L, Lieber CS. Early perivenular sclerosis in alcoholic fatty liver: an index of progressive liver injury. Gastroenterology 1977;73:646-50.
7. Womer TM, Lieber CS. Perivenular fibrosis as precursor lesion of cirrhosis. JAMA 1985;254:627-30.
8. Nonomura A, Mizukami Y, Unoura M, et al. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn 1992;27:521-8.
9. Matteoni C, Younossi ZM, McCullough A. Nonalcoholic fatty liver disease: A spectrum of clinical pathological severity. Gastroenterology 1999;116:1413-19.
10. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003;98:2042-7.
11. Jepsen P, Vilstrup H, Mellemkjaer L, et al. Prognosis of patients with a diagnosis of fatty liver - a registry-based cohort study. Hepatogastroenterology 2003;50:2101-4.
12. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
13. Monta A. Hepatitis C and steatosis. Semin Gastrointest Dis 2002;13:40-6.
14. Hezode C, Lonjon I, Roudot-Thoraval F, et al. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 2003;17:1031-7.
15. Ohato K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003;97:3036-43.
16. Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
17. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-57.
18. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002;10(suppl 2):97-104S.
19. Lebovitz HE. The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl 2003;134:18-27.
20. Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004;53:1020-23.
21. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
22. Szapary PO, Rader DJ. Pharmacological management of high triglycerides and low high-density lipaprotein cholesterol. Curr Opin Pharmacol 2001;1:113-20.
23. Elliott WJ. Is fixed combination therapy appropriate for initial hypertension treatment? Curr Hypertens Rep 2002;4:278-85.
24. Ali Raza J, Movahed A. Current concepts of cardiovascular diseases in diabetes mellitus. Int J Cardiol 2003;89:123-34.
25. Large V, Arner P. Regulation of lipalysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Diabetes Metab 1998;24:409-18.
26. Philipson LH. Beta-agonists and metabolism. J Allergy Clin Immunol 2002;110:S313-17.
27. Garg R, Tripathy D, Dandona P. Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. Curr Drug Targets 2003;4:487-92.
28. Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin Pnarmacother 2003;4:611-23.
29. Tadayyon M, Smith SA. Insulin sensitisation in the treatment of type 2 diabetes. Expert Opin Invest Drugs 2003;12:307-24.
30. Hoffmann IS, Cubeddu LX. Clustering of silent cardiovascular risk factors in apparently healthy Hispanics. J Hum Hypertens 2002; 16(suppl 1):S137-41.